These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [THE CURRENT STATUS OF FIBRINOLYTIC THERAPY]. KAPPERT A Med Klin; 1963 Nov; 58():1844-6. PubMed ID: 14100260 [No Abstract] [Full Text] [Related]
3. [THROMBOLYTIC THERAPY AND CHANGES IN FIBRINOLYTIC ACTIVITY]. DOUGLAS AS; MCNICOL GP Recenti Prog Med; 1964 Sep; 37():189-217. PubMed ID: 14229145 [No Abstract] [Full Text] [Related]
4. RADIOACTIVE (I-125) HUMAN PLASMA CLOTS FOR ASSAY OF THROMBOLYTIC ACTIVITY. HUME M J Lab Clin Med; 1964 Apr; 63():699-702. PubMed ID: 14155458 [No Abstract] [Full Text] [Related]
5. On the formation of different types of plasmin by streptokinase activation. MARKUS G; AMBRUS CM J Biol Chem; 1960 Jun; 235():1673-9. PubMed ID: 14421331 [No Abstract] [Full Text] [Related]
6. PITFALLS IN THE THROMBOLYTIC TREATMENT OF VENOUS OCCLUSION. AMERY A; VERMYLEN J; MAES H; VERSTRAETE M Vasc Dis; 1964 Mar; 1():89-93. PubMed ID: 14186547 [No Abstract] [Full Text] [Related]
7. [Research on the antifibrinolytic effect of 6-aminocaproic acid. III. Effect of 6-aminocaproic acid as an antidote to thrombolytic agents (plasmin, streptokinase)]. GIBELLI A Gazz Int Med Chir; 1962 Nov; 66():2444-50. PubMed ID: 13947688 [No Abstract] [Full Text] [Related]
8. THE PROACTIVATOR (PLASMINOGEN?) DETERMINATION IN PLASMA DURING FIBRINOLYTIC THERAPY. BLIX S Acta Med Scand; 1964 Nov; 176():649-50. PubMed ID: 14223542 [No Abstract] [Full Text] [Related]
9. [ON A METHOD FOR THE DETERMINATION OF PLASMA FIBRINOLYTIC ACTIVITY]. SHIRAI T Klin Wochenschr; 1964 Jun; 42():586-8. PubMed ID: 14236987 [No Abstract] [Full Text] [Related]
10. FIBRINOLYTIC AND ESTEROLYTIC ACTIVITY OF HUMAN PLASMA. ADAMIS DM; MANIATIS GM Thromb Diath Haemorrh; 1965 Jun; 13():484-91. PubMed ID: 14347870 [No Abstract] [Full Text] [Related]
11. Effects of epsilon-amino-caproic acid on prolactin-inactivating and fibrinolytic activities of streptokinase-activated plasminogen. HOPKINS TF; MEITES J Proc Soc Exp Biol Med; 1963 Apr; 112():830-2. PubMed ID: 13961684 [No Abstract] [Full Text] [Related]
12. The esterase activities of human plasmin during purification and subsequent activation by streptokinase or glycerol. ROBERTS PS J Biol Chem; 1960 Aug; 235():2262-6. PubMed ID: 14437833 [No Abstract] [Full Text] [Related]
14. THE EFFECT OF COPPER IONS ON CLOT LYSIS TIME IN THE FIBRINOLYTIC ASSAY OF STREPTOKINASE. BOGERT AB Thromb Diath Haemorrh; 1965 Jun; 13():477-83. PubMed ID: 14347869 [No Abstract] [Full Text] [Related]
15. SOME CONSIDERATIONS IN THE SYSTEMIC USE OF FIBRINOLYTIC AGENT. COON WW Mich Med; 1964 Jul; 63():488-90. PubMed ID: 14182774 [No Abstract] [Full Text] [Related]
16. FIBRINOLYSIS AND FIBRINOLYTIC AGENTS IN CLINICAL PRACTICE. (WITH SPECIAL REFERENCE TO STREPTOKINASE). JAMES DC; BROWSE NL Br J Clin Pract; 1964 Jun; 18():343-56. PubMed ID: 14169065 [No Abstract] [Full Text] [Related]
17. IMMUNOHISTOCHEMICAL STUDY OF THROMBOLYTIC MECHANISMS. BACK N; HIRAMOTO R; AMBRUS JL Blood; 1965 Jun; 25():1028-36. PubMed ID: 14294764 [No Abstract] [Full Text] [Related]